cover
Contact Name
Indra Hadi
Contact Email
profesionaljournalmedicine@gmail.com
Phone
-
Journal Mail Official
pt.internationalmedicaljournal@gmail.com
Editorial Address
Equity Tower. 49th Floor. Sudirman Street. Special Region of Jakarta, Indonesia
Location
Kota adm. jakarta selatan,
Dki jakarta
INDONESIA
The International Journal of Medical Science and Health Research
ISSN : 30481376     EISSN : 30481368     DOI : -
Core Subject : Health,
The International Journal of Medical Science and Health Research, published by International Medical Journal Corp. Ltd. is dedicated to providing physicians with the best research and important information in the world of medical research and science and to present the information in a format that is understandable and clinically useful. Committed to publishing multidisciplinary research that spans the entire spectrum of healthcare and medicine access, The American Journal of Medical Science and Health Research aims at an international audience of pharmacists, clinicians, medical ethicists, regulators, and researchers, providing an online forum for the rapid dissemination of recent research and perspectives in this area.
Articles 626 Documents
COMPREHENSIVE SYSTEMATIC REVIEW OF THE ROLE OF ARTIFICIAL INTELLIGENCE-BASED COMPUTER-AIDED DETECTION ENDOSCOPY IN COLON POLYPS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES Muhammad Thoriq Alhabib; Namira Assyfa Nurazizah; Fikri Arif Muhammad; Chaerunnisa Auliya Putu Sugiyarti; Greatavia Meanda Leslie; Srigita Varsha; Dwi Putri Wijayanti; Fitri Nurina Septiana; Bernita Nur Cahyani; Shelda Syifa’ Azzahra; Muhamad Luthfi Asyhar; Charles Sanjaya
The International Journal of Medical Science and Health Research Vol. 49 No. 2 (2026): The International Journal of Medical Science and Health Research
Publisher : International Medical Journal Corp. Ltd

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70070/kcmyh598

Abstract

Background and aims: Adenoma detection rate (ADR) is the principal quality indicator of colonoscopy and is inversely associated with post-colonoscopy colorectal cancer (PCCRC). Artificial intelligence (AI)-based computer-aided detection (CADe) systems built on deep convolutional neural networks provide real-time visual alerts for suspected polyps. We aimed to comprehensively synthesise randomised and primary non-randomised evidence published in the last 15 years on the efficacy, effectiveness and diagnostic performance of CADe-assisted colonoscopy for colorectal polyp detection. Methods: The study strictly adhered to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 guidelines. Eligible designs were randomised controlled trials (RCTs), comparative studies, cohorts and case series; systematic reviews and meta-analyses were excluded from the evidence base and considered only in the discussion. Risk of bias was assessed with RoB 2, ROBINS-I and the JBI case-series checklist. Random-effects meta-analyses used restricted maximum-likelihood heterogeneity estimation with Hartung–Knapp–Sidik–Jonkman (HKSJ) confidence intervals and 95% prediction intervals (PI). Certainty of evidence was rated with GRADE. Results: Sixty-three studies were included (43 RCTs, 12 non-randomised comparative studies and 8 case/validation series; more than 79,000 colonoscopies). In 34 parallel-group RCTs (n = 34,010), CADe increased ADR from 41.4% to 47.4% (risk ratio [RR] 1.16 (95% CI 1.11–1.22); I² = 66%; 95% PI 0.94–1.43; low certainty). CADe halved the adenoma miss rate in tandem RCTs (RR 0.49 (95% CI 0.32–0.75); moderate certainty), increased polyp detection (RR 1.21 (95% CI 1.08–1.35)) and adenomas per colonoscopy (mean difference 0.27 (95% CI 0.15–0.38)), but did not increase detection of advanced adenoma/advanced neoplasia (RR 1.04 (95% CI 0.95–1.14)) or, with statistical certainty, serrated lesions (RR 1.48 (95% CI 0.80–2.73)). The relative benefit declined with higher control-arm ADR (meta-regression P < 0.001; R² = 67%), from RR 1.45 when baseline ADR was below 30% to RR 1.08 when it was 45% or higher, and attenuated in more recent and FIT-positive trials. In non-randomised real-world cohorts the pooled effect was smaller and non-significant (odds ratio 1.20 (95% CI 0.98–1.46); very low certainty). Small-study effects were present (Egger P = 0.004), although the trim-and-fill-adjusted estimate remained favourable (RR 1.11). Stand-alone validation series reported per-lesion or per-image sensitivities of approximately 87–100%. Conclusions: CADe-assisted colonoscopy consistently increases the detection of predominantly diminutive, non-advanced adenomas and reduces miss rates, with the greatest gains among lower-performing endoscopists. Its effect on advanced neoplasia, serrated lesions and, ultimately, PCCRC incidence remains unproven, and benefits are attenuated in high-performing and real-world settings. Implementation should be targeted, monitored and coupled with strategies that mitigate automation bias and deskilling.
CYTOKINE BIOMARKERS FOR THE PREDICTION OF CYTOKINE RELEASE SYNDROME IN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY: A COMPREHENSIVE SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS AND PRIMARY STUDIES Muhammad Thoriq Alhabib; Namira Assyfa Nurazizah; Fikri Arif Muhammad; Chaerunnisa Auliya Putu Sugiyarti; Greatavia Meanda Leslie; Srigita Varsha; Dwi Putri Wijayanti; Fitri Nurina Septiana; Bernita Nur Cahyani; Shelda Syifa’ Azzahra; Muhamad Luthfi Asyhar; Charles Sanjaya
The International Journal of Medical Science and Health Research Vol. 49 No. 2 (2026): The International Journal of Medical Science and Health Research
Publisher : International Medical Journal Corp. Ltd

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70070/bhxfav87

Abstract

Background. Cytokine release syndrome (CRS) remains the defining acute toxicity of chimeric antigen receptor (CAR) T-cell therapy, and the capacity to identify, before clinical deterioration, the minority of recipients who will progress to high-grade disease would allow pre-emptive rather than reactive management. Individual cohorts have nominated a long list of candidate cytokine biomarkers, but their effect sizes, measurement windows and discriminative performance have never been quantitatively consolidated across the full breadth of CAR-T indications. Objective. To quantify the association between circulating cytokine biomarkers and severe CRS after CAR-T cell therapy, to compare cytokines with routinely available acute-phase and endothelial indices, and to estimate the discriminative accuracy of composite multi-analyte models. Methods. The study strictly adhered to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 guidelines. Randomised controlled trials, comparative studies, cohort studies and case series of at least ten patients that reported a quantified cytokine biomarker and graded CRS were eligible; systematic reviews and meta-analyses were excluded from pooling and reserved for contextual discussion. Risk of bias was appraised with ROBINS-I and Cochrane RoB 2. DerSimonian–Laird random-effects models pooled odds ratios per ten-fold increment of each analyte, with prediction intervals, Egger and Begg tests, trim-and-fill, leave-one-out influence analysis, meta-regression and GRADE certainty rating. Diagnostic accuracy of composite models was synthesised bivariately with a summary receiver-operating characteristic curve. Results. Thirty-two primary studies comprising 4,381 participants were included, of which 27 contributed to quantitative synthesis. Interferon-gamma showed the strongest pooled association with severe CRS (odds ratio 2.65 (95% CI 2.13–3.30); I² 34%), followed by interleukin-6 (2.49 (95% CI 2.06–3.01); I² 35%), the monocyte–macrophage chemokine axis of interleukin-8 and MCP-1 (2.24 (95% CI 1.77–2.83)), interleukin-10 (2.15 (95% CI 1.78–2.60)), interleukin-2 and its soluble receptor (1.84 (95% CI 1.45–2.35)) and interleukin-15 (1.70 (95% CI 1.36–2.11)). Tumour necrosis factor-alpha was not significantly associated with severe CRS (1.18 (95% CI 0.96–1.46)). Acute-phase reactants performed materially less well than effector cytokines (1.50 (95% CI 1.30–1.74)), whereas the endothelial activation and stress index separated severe from non-severe disease with a standardised mean difference of 0.49 (95% CI 0.34–0.63). Pre-infusion composite models carried a pooled odds ratio of 2.01 (95% CI 1.70–2.38), significantly weaker than post-infusion sampling (1.60 versus 2.19; P for interaction = 0.002). Composite multi-analyte models achieved a pooled sensitivity of 77.2% (95% CI 70.5–82.7), specificity of 84.4% (79.0–88.6) and a diagnostic odds ratio of 21.0, with a mean reported area under the curve of 0.85. Certainty of evidence was low for most individual analytes and moderate for EASIX. Conclusions. Effector cytokines generated by the CAR T cell itself and by the myeloid compartment it recruits are reproducibly associated with severe CRS, and composite models combining two or three analytes with a routine haematological variable approach the discriminative performance required for clinical deployment. The evidence base is nonetheless constrained by platform heterogeneity, in-sample threshold derivation and the near-absence of randomised evidence for biomarker-triggered intervention. A biomarker-stratified randomised trial of pre-emptive cytokine blockade is now the logical and overdue next step.
STEVENS–JOHNSON SYNDROME–TOXIC EPIDERMAL NECROLYSIS OVERLAP SUSPECTED TO BE INDUCED BY A POLYPHARMACY COMPOUNDED PREPARATION FOR TRIGEMINAL NEURALGIA - THE CHALLENGE OF DRUG CAUSALITY ASSESSMENT: A CASE REPORT Alifa Puspita Pramasari; Galuh Dyah Puspitasari; Hafid Rakasdian
The International Journal of Medical Science and Health Research Vol. 49 No. 2 (2026): The International Journal of Medical Science and Health Research
Publisher : International Medical Journal Corp. Ltd

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70070/x8dfz371

Abstract

Background. Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe mucocutaneous reactions that are predominantly drug-induced. Identification of the culprit drug becomes difficult when a patient receives compounded preparations containing multiple active ingredients at once, a practice still encountered in primary care. Case. A 62-year-old woman presented with a generalized eruption of dusky red macules that progressed to flaccid bullae and erosions within hours, accompanied by mucosal involvement with a positive Nikolsky sign. An epidermal detachment of 23.5% placed this case in the SJS–TEN overlap category. During the preceding 30 days, the patient had received seven prescriptions of compounded preparations for trigeminal neuralgia, with a composition that changed at almost every visit, including carbamazepine, three non-steroidal anti-inflammatory drugs, paracetamol, triamcinolone, gabapentin, and diazepam. SCORTEN on admission was 2, with a predicted mortality of 12.1%. ALDEN causality assessment of all active ingredients yielded two drugs with an identical score of 5, i.e., the probable category, namely carbamazepine and meloxicam; therefore, a single culprit could not be established. Management and outcome. All suspected drugs were discontinued, and the patient received intravenous methylprednisolone, wound care with 0.9% NaCl compresses and topical antibiotics, as well as mucosal care. Lesion progression ceased within 24 hours of drug withdrawal, re-epithelialization began on day 7, and the patient was discharged on hospital day 11 with lesions that had partly evolved into post-inflammatory hypopigmented and hyperpigmented macules. Conclusion. Prescribing multi-ingredient compounded preparations increases the risk of severe drug reactions while permanently obscuring identification of the culprit, because drug provocation testing is contraindicated. Structured causality assessment and visit-by-visit documentation of exposure are minimum requirements before a drug is declared the culprit and recorded as a lifelong contraindication for the patient.
ACUTE HYPOXEMIC RESPIRATORY FAILURE WITH SEVERE HYPERLACTATEMIA AND MIXED ACID–BASE DISORDER IN A PATIENT WITH PREVIOUS MYOCARDIAL INFARCTION: A CASE REPORT Budi Anugrah; Hersa Donantya Daneswara
The International Journal of Medical Science and Health Research Vol. 49 No. 2 (2026): The International Journal of Medical Science and Health Research
Publisher : International Medical Journal Corp. Ltd

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70070/r7ygkh82

Abstract

Introduction: Acute heart failure (AHF) presenting as acute pulmonary edema is a leading cause of acute hypoxemic respiratory failure (AHRF). Elevated lactate identifies organ injury and a worse prognosis in AHF even without overt hypoperfusion, and lactate combined with acidemia strongly modifies mortality in cardiogenic shock; when severe hyperlactatemia coexists with a primary respiratory alkalosis, a near-normal pH may conceal the true metabolic severity.1–3 Case illustration: A 48-year-old man with a previous ST-elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention (PCI) and a prior episode of AHF presented with dyspnea since the previous night, respiratory rate 41 breaths/min, SpO2 78% on room air (87% on a non-rebreathing mask), blood pressure 148/103 mmHg, heart rate 120 beats/min, warm extremities and bilateral crackles with wheezing. Arterial blood gas (reported FiO2 0.81) showed pH 7.35, PaCO2 21 mmHg, PaO2 52 mmHg, HCO3− 11.8 mmol/L, base excess −14 mmol/L and lactate 11.20 mmol/L; PaCO2 below the Winter's range (23.7–27.7 mmHg) indicated a concurrent primary respiratory alkalosis. High-sensitivity troponin I was 65.2 pg/mL (≈1.7 × upper reference limit), creatinine 1.84 mg/dL, potassium 2.8 mmol/L and glucose 300 mg/dL. Despite nitroglycerin, furosemide and mask oxygen he required intubation, after which high respiratory drive (total rate 43 breaths/min; tidal volume ≈10.6 mL/kg predicted body weight), severe hypoxemia (SpO2 93% on FiO2 0.85) and a fall in blood pressure to 101/55 mmHg were documented.4–6 Discussion: The ≈13% reduction in arterial oxygen content could not by itself explain a lactate of 11.2 mmol/L, implying superimposed normotensive low-output hypoperfusion, catecholamine-driven aerobic glycolysis—mirrored by hypokalemia and hyperglycemia—alkalosis-enhanced glycolysis, increased work of breathing and reduced clearance. The near-normal pH concealed a profound base deficit, a metabolic–hemodynamic discordance poorly captured by blood pressure-based staging, while vigorous post-intubation effort carried a risk of patient self-inflicted lung injury.7–10 Conclusion: In AHF complicated by AHRF, severe hyperlactatemia with a mixed acid–base disorder is a high-risk phenotype even when blood pressure is preserved. Systematic acid–base analysis, serial lactate, early echocardiography and lung ultrasound, timely evaluation for acute coronary syndrome, potassium repletion before or with insulin and diuretics, and lung-protective ventilation that controls respiratory drive are essential.11,12
EFFICACY OF ORAL NIFEDIPINE VERSUS LABETALOL IN THE EMERGENCY MANAGEMENT OF HYPERTENSIVE CRISIS IN PREGNANCY: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES Made Krisna Wibawa Pramartha
The International Journal of Medical Science and Health Research Vol. 49 No. 2 (2026): The International Journal of Medical Science and Health Research
Publisher : International Medical Journal Corp. Ltd

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70070/z48mzv70

Abstract

Introduction: Hypertensive disorders complicate one in ten pregnancies and remain leading causes of maternal mortality worldwide. Severe hypertension (SBP ≥160 mmHg and/or DBP ≥110 mmHg) constitutes an obstetric emergency due to imminent risks of intracerebral hemorrhage, eclampsia, pulmonary edema, and placental abruption. Oral nifedipine and labetalol are the most widely used first-line agents, yet comparative evidence remains fragmented. This review aimed to determine whether oral nifedipine differs from labetalol in acute control of hypertensive crisis in pregnancy across fifteen pre-specified clinical outcomes. Methods: A systematic review was conducted per PRISMA 2020 guidelines. Eligible designs included RCTs, quasi-experimental trials, prospective/retrospective cohorts, case-control, and cross-sectional studies comparing nifedipine with labetalol in pregnant women with severe hypertension. Risk of bias was appraised with Cochrane RoB 2 and ROBINS-I; certainty with GRADE. A binormal ROC reconstruction was performed for time-to-target blood pressure, with AUC representing probability of earlier attainment. Results: Twenty-one primary studies (15 RCTs, 1 quasi-experimental, 2 prospective cohorts, 3 retrospective cohorts) comprising ≥9,889 pregnant women from ten countries were included. Oral nifedipine reached target BP significantly faster than labetalol: pooled MD -9.10 minutes (95% CI -13.69 to -4.51; τ²=11.55; I²=44.2%). Reconstructed pooled AUC was 0.668 (95% CI 0.609-0.727; I²=0.0%), significantly exceeding 0.500. Nifedipine required fewer doses, produced greater systolic/diastolic reduction, and increased urine output. Maternal/perinatal adverse events, caesarean delivery, fetal heart-rate abnormality, Apgar<7, and NICU admission did not differ significantly. One large observational cohort favored labetalol for composite maternal morbidity (aRR 1.33, 95% CI 1.07-1.64). Risk of bias was low in 5/15 RCTs, moderate-to-serious in all non-randomized studies. GRADE certainty was moderate for time-to-target and dose requirement, low/very low for patient-important outcomes. Discussion: Nifedipine's pharmacodynamic superiority in speed and dose economy is consistent, mechanistically coherent, and reproducible. However, speed is a surrogate outcome; the largest observational dataset raises signals of increased eclampsia, HELLP, and renal failure with nifedipine. The AUC of 0.668 quantifies the advantage as modest—statistically significant but far from the >0.80 threshold justifying categorical protocol change. Conclusion: Oral nifedipine controls hypertensive crisis significantly faster with fewer doses than labetalol, with a moderate discriminative advantage (AUC 0.668) and equivalent maternal/perinatal safety in randomized evidence. Requiring no IV access, infusion pump, or continuous cardiotocography, nifedipine should be regarded as a legitimate first-line option—and in resource-constrained settings, the preferred option.
EARLY FAILURE OF ACETABULAR ORIF IN SEVERE OBESITY: RETHINKING SALVAGE STRATEGY IN A YOUNG PATIENT Putu Gana Cahya Narta Putra; Agus Eka Wiradiputra
The International Journal of Medical Science and Health Research Vol. 49 No. 2 (2026): The International Journal of Medical Science and Health Research
Publisher : International Medical Journal Corp. Ltd

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70070/p65q6843

Abstract

Introduction: Open reduction and internal fixation (ORIF) remains the gold standard for displaced acetabular fractures in young patients. However, severe obesity imposes extreme cyclic mechanical loading that may render ORIF biologically futile regardless of surgical technique. When fixation fails in this setting, salvage arthroplasty presents a formidable challenge,compounded further by concurrent sciatic nerve injury and the inherent tension between joint preservation and mechanical reality in a young patient. We report this case to challenge the default surgical paradigm and propose a framework for rethinking decision-making in this high-risk intersection. Case Presentation: A 35-year-old male weighing 120 kg sustained a left posterior-superior acetabular fracture following a motor vehicle accident and underwent ORIF at an outside institution two days post-injury. Within weeks, he developed progressive hip pain, wound erythema, systemic chills, and clinical hip subluxation. Plain radiograph and CT 3D reconstruction confirmed implant failure with severe acetabular comminution and loss of femoral head containment. Sciatic nerve palsy and leg length discrepancy were established on examination. After careful pre-operative planning, bipolar hemiarthroplasty via a posterolateral approach was performed at our institution (Bali Royal Hospital). Intraoperatively, the retained posterior column plate provided structural scaffolding for the bipolar articulation. The patient was discharged on post-operative day five with residual lower limb paraesthesias managed conservatively. Discussion: The failure in this case was not incidental,it was biomechanically foreseeable. In a 120 kg patient, peak hip joint reactive forces may exceed 900 kg per step, subjecting a comminuted posterior acetabular construct to repetitive cantilever bending that promotes fatigue failure at the implant-bone interface before consolidation occurs. A structured counterfactual analysis raises a provocative question: had primary arthroplasty been chosen at the index procedure, would the patient have been spared a second major operation, cumulative sciatic nerve risk from two posterior approaches within three months, and a two-month interval of pain and progressive joint destruction? Current literature supports the durability of modern arthroplasty constructs in this setting, yet the paradigm of ORIF as the default 'joint-preserving' choice in young patients persists,even when the joint, under these mechanical conditions, may not be preservable. Conclusion: Bipolar hemiarthroplasty is a viable salvage strategy following early ORIF failure in a severely obese young patient with posterior-superior acetabular fracture. The retained posterior column hardware can serve as a structural scaffold for bipolar articulation in cases of compromised acetabular bone stock. Timely recognition of failure and decisive surgical re-intervention are critical to preventing irreversible joint destruction. Clinical Importance: Severe obesity must be recognised not merely as a comorbidity but as a fundamental biomechanical contraindication to standard ORIF constructs in comminuted acetabular fractures. Surgeons should explicitly discuss primary arthroplasty as an alternative,even in young patients,when the convergence of extreme BMI, posterior wall comminution, and suboptimal bone quality predicts fixation failure. The question is no longer whether we can fix it, but whether fixing it serves the patient.

Filter by Year

2022 2026


Filter By Issues
All Issue Vol. 49 No. 2 (2026): The International Journal of Medical Science and Health Research Vol. 48 No. 5 (2026): The International Journal of Medical Science and Health Research Vol. 48 No. 3 (2026): The International Journal of Medical Science and Health Research Vol. 48 No. 2 (2026): The International Journal of Medical Science and Health Research Vol. 48 No. 1 (2026): The International Journal of Medical Science and Health Research Vol. 47 No. 2 (2026): The International Journal of Medical Science and Health Research Vol. 47 No. 1 (2026): The International Journal of Medical Science and Health Research Vol. 46 No. 2 (2026): The International Journal of Medical Science and Health Research Vol. 46 No. 1 (2026): The International Journal of Medical Science and Health Research Vol. 45 No. 2 (2026): The International Journal of Medical Science and Health Research Vol. 45 No. 1 (2026): The International Journal of Medical Science and Health Research Vol. 44 No. 2 (2026): The International Journal of Medical Science and Health Research Vol. 44 No. 1 (2026): The International Journal of Medical Science and Health Research Vol. 43 No. 2 (2026): The International Journal of Medical Science and Health Research Vol. 43 No. 1 (2026): The International Journal of Medical Science and Health Research Vol. 42 No. 2 (2026): The International Journal of Medical Science and Health Research Vol. 42 No. 1 (2026): The International Journal of Medical Science and Health Research Vol. 41 No. 2 (2026): The International Journal of Medical Science and Health Research Vol. 41 No. 1 (2026): The International Journal of Medical Science and Health Research Vol. 40 No. 2 (2026): The International Journal of Medical Science and Health Research Vol. 40 No. 1 (2026): The International Journal of Medical Science and Health Research Vol. 39 No. 2 (2026): The International Journal of Medical Science and Health Research Vol. 39 No. 1 (2026): The International Journal of Medical Science and Health Research Vol. 38 No. 2 (2026): The International Journal of Medical Science and Health Research Vol. 38 No. 1 (2026): The International Journal of Medical Science and Health Research Vol. 37 No. 2 (2026): The International Journal of Medical Science and Health Research Vol. 37 No. 1 (2026): The International Journal of Medical Science and Health Research Vol. 36 No. 2 (2026): The International Journal of Medical Science and Health Research Vol. 36 No. 1 (2026): The International Journal of Medical Science and Health Research Vol. 35 No. 2 (2026): The International Journal of Medical Science and Health Research Vol. 35 No. 1 (2026): The International Journal of Medical Science and Health Research Vol. 34 No. 2 (2026): The International Journal of Medical Science and Health Research Vol. 34 No. 1 (2026): The International Journal of Medical Science and Health Research Vol. 33 No. 2 (2026): The International Journal of Medical Science and Health Research Vol. 33 No. 1 (2026): The International Journal of Medical Science and Health Research Vol. 32 No. 2 (2026): The International Journal of Medical Science and Health Research Vol. 32 No. 1 (2026): The International Journal of Medical Science and Health Research Vol. 31 No. 2 (2026): The International Journal of Medical Science and Health Research Vol. 31 No. 1 (2026): The International Journal of Medical Science and Health Research Vol. 30 No. 2 (2026): The International Journal of Medical Science and Health Research Vol. 30 No. 1 (2026): The International Journal of Medical Science and Health Research Vol. 29 No. 2 (2026): The International Journal of Medical Science and Health Research Vol. 29 No. 1 (2026): The International Journal of Medical Science and Health Research Vol. 28 No. 2 (2026): The International Journal of Medical Science and Health Research Vol. 28 No. 1 (2026): The International Journal of Medical Science and Health Research Vol. 27 No. 2 (2026): The International Journal of Medical Science and Health Research Vol. 27 No. 1 (2026): The International Journal of Medical Science and Health Research Vol. 26 No. 2 (2026): The International Journal of Medical Science and Health Research Vol. 26 No. 1 (2026): The International Journal of Medical Science and Health Research Vol. 25 No. 2 (2026): The International Journal of Medical Science and Health Research Vol. 25 No. 1 (2026): The International Journal of Medical Science and Health Research Vol. 24 No. 2 (2026): The International Journal of Medical Science and Health Research Vol. 23 No. 1 (2026): The International Journal of Medical Science and Health Research Vol. 18 No. 12 (2025): The International Journal of Medical Science and Health Research Vol. 18 No. 11 (2025): The International Journal of Medical Science and Health Research Vol. 18 No. 10 (2025): The International Journal of Medical Science and Health Research Vol. 24 No. 1 (2025): The International Journal of Medical Science and Health Research Vol. 23 No. 2 (2025): The International Journal of Medical Science and Health Research Vol. 22 No. 4 (2025): The International Journal of Medical Science and Health Research Vol. 22 No. 3 (2025): The International Journal of Medical Science and Health Research Vol. 22 No. 2 (2025): The International Journal of Medical Science and Health Research Vol. 22 No. 1 (2025): The International Journal of Medical Science and Health Research Vol. 21 No. 4 (2025): The International Journal of Medical Science and Health Research Vol. 21 No. 3 (2025): The International Journal of Medical Science and Health Research Vol. 21 No. 2 (2025): The International Journal of Medical Science and Health Research Vol. 21 No. 1 (2025): The International Journal of Medical Science and Health Research Vol. 20 No. 4 (2025): The International Journal of Medical Science and Health Research Vol. 20 No. 3 (2025): The International Journal of Medical Science and Health Research Vol. 20 No. 2 (2025): The International Journal of Medical Science and Health Research Vol. 20 No. 1 (2025): The International Journal of Medical Science and Health Research Vol. 19 No. 4 (2025): The International Journal of Medical Science and Health Research Vol. 19 No. 3 (2025): The International Journal of Medical Science and Health Research Vol. 19 No. 2 (2025): The International Journal of Medical Science and Health Research Vol. 19 No. 1 (2025): The International Journal of Medical Science and Health Research Vol. 18 No. 9 (2025): The International Journal of Medical Science and Health Research Vol. 18 No. 8 (2025): The International Journal of Medical Science and Health Research Vol. 18 No. 7 (2025): The International Journal of Medical Science and Health Research Vol. 18 No. 6 (2025): The International Journal of Medical Science and Health Research Vol. 18 No. 5 (2025): The International Journal of Medical Science and Health Research Vol. 18 No. 4 (2025): The International Journal of Medical Science and Health Research Vol. 18 No. 3 (2025): The International Journal of Medical Science and Health Research Vol. 18 No. 2 (2025): The International Journal of Medical Science and Health Research Vol. 18 No. 1 (2025): The International Journal of Medical Science and Health Research Vol. 17 No. 8 (2025): The International Journal of Medical Science and Health Research Vol. 17 No. 7 (2025): The International Journal of Medical Science and Health Research Vol. 17 No. 6 (2025): The International Journal of Medical Science and Health Research Vol. 17 No. 5 (2025): The International Journal of Medical Science and Health Research Vol. 17 No. 4 (2025): The International Journal of Medical Science and Health Research Vol. 17 No. 3 (2025): The International Journal of Medical Science and Health Research Vol. 17 No. 2 (2025): The International Journal of Medical Science and Health Research Vol. 17 No. 1 (2025): The International Journal of Medical Science and Health Research Vol. 16 No. 8 (2025): The International Journal of Medical Science and Health Research Vol. 16 No. 7 (2025): The International Journal of Medical Science and Health Research Vol. 16 No. 6 (2025): The International Journal of Medical Science and Health Research Vol. 16 No. 5 (2025): The International Journal of Medical Science and Health Research Vol. 16 No. 4 (2025): The International Journal of Medical Science and Health Research Vol. 16 No. 3 (2025): The International Journal of Medical Science and Health Research Vol. 16 No. 2 (2025): The International Journal of Medical Science and Health Research Vol. 16 No. 1 (2025): The International Journal of Medical Science and Health Research Vol. 15 No. 7 (2025): The International Journal of Medical Science and Health Research Vol. 15 No. 6 (2025): The International Journal of Medical Science and Health Research Vol. 15 No. 5 (2025): The International Journal of Medical Science and Health Research Vol. 15 No. 4 (2025): The International Journal of Medical Science and Health Research Vol. 15 No. 3 (2025): The International Journal of Medical Science and Health Research Vol. 15 No. 2 (2025): The International Journal of Medical Science and Health Research Vol. 15 No. 1 (2025): The International Journal of Medical Science and Health Research Vol. 14 No. 6 (2025): The International Journal of Medical Science and Health Research Vol. 14 No. 5 (2025): The International Journal of Medical Science and Health Research Vol. 14 No. 4 (2025): The International Journal of Medical Science and Health Research Vol. 14 No. 3 (2025): The International Journal of Medical Science and Health Research Vol. 14 No. 2 (2025): The International Journal of Medical Science and Health Research Vol. 14 No. 1 (2025): The International Journal of Medical Science and Health Research Vol. 13 No. 7 (2025): The International Journal of Medical Science and Health Research Vol. 13 No. 6 (2025): The International Journal of Medical Science and Health Research Vol. 13 No. 5 (2025): The International Journal of Medical Science and Health Research Vol. 13 No. 4 (2025): The International Journal of Medical Science and Health Research Vol. 13 No. 3 (2025): The International Journal of Medical Science and Health Research Vol. 13 No. 2 (2025): The International Journal of Medical Science and Health Research Vol. 13 No. 1 (2025): The International Journal of Medical Science and Health Research Vol. 12 No. 7 (2025): The International Journal of Medical Science and Health Research Vol. 12 No. 6 (2025): The International Journal of Medical Science and Health Research Vol. 12 No. 5 (2025): The International Journal of Medical Science and Health Research Vol. 12 No. 4 (2025): The International Journal of Medical Science and Health Research Vol. 12 No. 3 (2025): The International Journal of Medical Science and Health Research Vol. 12 No. 2 (2025): The International Journal of Medical Science and Health Research Vol. 12 No. 1 (2025): The International Journal of Medical Science and Health Research Vol. 11 No. 1 (2025): The International Journal of Medical Science and Health Research Vol. 10 No. 6 (2025): The International Journal of Medical Science and Health Research Vol. 10 No. 5 (2025): The International Journal of Medical Science and Health Research Vol. 10 No. 4 (2025): The International Journal of Medical Science and Health Research Vol. 10 No. 3 (2025): The International Journal of Medical Science and Health Research Vol. 10 No. 2 (2025): The International Journal of Medical Science and Health Research Vol. 10 No. 1 (2025): The International Journal of Medical Science and Health Research Vol. 9 No. 5 (2025): The International Journal of Medical Science and Health Research Vol. 9 No. 4 (2025): The International Journal of Medical Science and Health Research Vol. 9 No. 3 (2025): The International Journal of Medical Science and Health Research Vol. 9 No. 2 (2025): The International Journal of Medical Science and Health Research Vol. 9 No. 1 (2025): The International Journal of Medical Science and Health Research Vol. 8 No. 4 (2025): The International Journal of Medical Science and Health Research Vol. 8 No. 3 (2025): The International Journal of Medical Science and Health Research Vol. 8 No. 2 (2025): The International Journal of Medical Science and Health Research Vol. 8 No. 1 (2025): The International Journal of Medical Science and Health Research Vol. 7 No. 4 (2024): The International Journal of Medical Science and Health Research Vol. 7 No. 3 (2024): The International Journal of Medical Science and Health Research Vol. 7 No. 2 (2024): The International Journal of Medical Science and Health Research Vol. 7 No. 1 (2024): The International Journal of Medical Science and Health Research Vol. 6 No. 3 (2024): The International Journal of Medical Science and Health Research Vol. 6 No. 2 (2024): The International Journal of Medical Science and Health Research Vol. 6 No. 1 (2024): The International Journal of Medical Science and Health Research Vol. 5 No. 8 (2024): The International Journal of Medical Science and Health Research Vol. 5 No. 7 (2024): The International Journal of Medical Science and Health Research Vol. 5 No. 6 (2024): The International Journal of Medical Science and Health Research Vol. 5 No. 5 (2024): The International Journal of Medical Science and Health Research Vol. 5 No. 4 (2024): The International Journal of Medical Science and Health Research Vol. 5 No. 3 (2024): The International Journal of Medical Science and Health Research Vol. 5 No. 2 (2024): The International Journal of Medical Science and Health Research Vol. 5 No. 1 (2024): The International Journal of Medical Science and Health Research Vol. 4 No. 5 (2024): The International Journal of Medical Science and Health Research Vol. 4 No. 4 (2024): The International Journal of Medical Science and Health Research Vol. 4 No. 3 (2024): The International Journal of Medical Science and Health Research Vol. 4 No. 2 (2024): The International Journal of Medical Science and Health Research Vol. 4 No. 1 (2024): The International Journal of Medical Science and Health Research Vol. 3 No. 2 (2024): The International Journal of Medical Science and Health Research Vol. 3 No. 1 (2024): The International Journal of Medical Science and Health Research Vol. 2 No. 8 (2024): The International Journal of Medical Science and Health Research Vol. 2 No. 7 (2024): The International Journal of Medical Science and Health Research Vol. 2 No. 6 (2024): The International Journal of Medical Science and Health Research Vol. 2 No. 5 (2024): The International Journal of Medical Science and Health Research Vol. 2 No. 4 (2024): The International Journal of Medical Science and Health Research Vol. 2 No. 3 (2024): The International Journal of Medical Science and Health Research Vol. 2 No. 2 (2024): The International Journal of Medical Science and Health Research Vol. 2 No. 1 (2024): The International Journal of Medical Science and Health Research Vol. 1 No. 6 (2024): The International Journal of Medical Science and Health Research Vol. 1 No. 5 (2024): The International Journal of Medical Science and Health Research Vol. 1 No. 4 (2024): The International Journal of Medical Science and Health Research Vol. 1 No. 3 (2024): The International Journal of Medical Science and Health Research Vol. 1 No. 2 (2024) Vol. 1 No. 1 (2024) Vol. 1 No. 1 (2022): The International Journal of Medical Science and Health Research More Issue